Brokerages forecast that Spero Therapeutics Inc (NASDAQ:SPRO) will report $2.03 million in sales for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Spero Therapeutics’ earnings, with the lowest sales estimate coming in at $1.25 million and the highest estimate coming in at $2.50 million. Spero Therapeutics posted sales of $660,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 207.6%. The company is expected to announce its next quarterly earnings results on Thursday, November 14th.
On average, analysts expect that Spero Therapeutics will report full-year sales of $14.23 million for the current fiscal year, with estimates ranging from $13.62 million to $15.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $11.15 million, with estimates ranging from $10.00 million to $11.90 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%. The business had revenue of $2.16 million for the quarter, compared to the consensus estimate of $6.95 million.
Shares of SPRO stock traded down $0.12 during mid-day trading on Wednesday, reaching $10.35. 15,600 shares of the company’s stock traded hands, compared to its average volume of 63,342. Spero Therapeutics has a 12 month low of $5.52 and a 12 month high of $14.48. The firm has a 50 day moving average price of $10.70 and a two-hundred day moving average price of $11.35. The company has a debt-to-equity ratio of 0.04, a quick ratio of 13.66 and a current ratio of 13.66. The firm has a market capitalization of $195.37 million, a PE ratio of -3.98 and a beta of 2.09.
Several hedge funds have recently modified their holdings of SPRO. Acadian Asset Management LLC bought a new position in Spero Therapeutics in the 2nd quarter worth $25,000. Marshall Wace LLP bought a new position in Spero Therapeutics in the 1st quarter worth $39,000. Northern Trust Corp boosted its holdings in Spero Therapeutics by 6.1% in the 2nd quarter. Northern Trust Corp now owns 93,750 shares of the company’s stock worth $1,079,000 after buying an additional 5,416 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Spero Therapeutics by 30.7% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 25,118 shares of the company’s stock worth $290,000 after buying an additional 5,895 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in Spero Therapeutics by 187.9% in the 2nd quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after buying an additional 8,915 shares during the period. 50.97% of the stock is owned by hedge funds and other institutional investors.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Recommended Story: How to start trading in the forex market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.